In acute infective exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (COPD), adding erdosteine to standard treatment significantly modified the outcome by improving the ...
The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...
Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...
In COPD, muscular atrophy is a significant risk factor for death and may prolong patients’ hospital length of stay.
1,8,13,14 Lack of familiarity with treatment guidelines among primary care providers may contribute to underdiagnosis of COPD. In an analysis of 2006 survey data drawn from 784 active US primary ...
The precise mechanism through which fluticasone furoate affects COPD and asthma symptoms is ... involved in inflammation. The pharmacologic effects of beta 2-adrenoceptor agonist drugs, including ...
The effect of erdosteine on mucus rheological properties was evaluated in patients with exacerbation of COPD. [24] Patients ... at day 3 and at the end of the treatment compared with the placebo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback